JIN-A02, a fourth-generation, highly effective tyrosine kinase inhibitor with intracranial activity, targeting EGFR C797S mutations in NSCLC

被引：7
|
作者：
Yun, M. R. [1 ]
Yu, M. R. [2 ]
Duggirala, K. B. [3 ]
Lee, K. [3 ]
Lim, S. M. [4 ]
Jo, A. [5 ]
Seah, E. [6 ]
Kim, C. [7 ]
Cho, B. C. [8 ]
机构：
[1] Yonsei Univ, Yonsei New Il Han Inst Integrat Lung Canc Res, Severance Biomed Sci Inst, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Dept Res Support, Yonsei Biomed Res Inst, Seoul, South Korea
[3] Korea Res Inst Chem Technol, Bio & Drug Discovery Div, Daejeon, South Korea
[4] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[5] J INTS Bio, Seoul, South Korea
[6] J INTS Bio, R&D, Seoul, South Korea
[7] J INTS Bio, Med, Seoul, South Korea
[8] Yonsei Univ, Med Oncol Dept 501, ABMRC, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
999P
引用
收藏
页码：S1010 / S1011
页数：2
相关论文
共 41 条
  • [1] JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC
    Yun, M. R.
    Yu, M. R.
    Duggirala, K. B.
    Lee, K.
    Jo, A.
    Seah, E.
    Kim, C.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S69 - S70
  • [2] Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance
    Patil, Bhatu R.
    Patel, Harun M.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 283
  • [3] Compound A, a fourth-generation allosteric inhibitor, a potent and highly selective EGFR with L858R activating and C797S resistance mutations for the treatment of NSCLC
    Byeon, Yeji
    Jung, Seung Hee
    Yoon, Daseul
    Kang, Seock Yong
    Park, Jiyeon
    Jo, Hyeim
    Choi, Seong-Il
    Park, Somyi
    Lee, Seung-chul
    Tae, Yang Hun
    Kim, Tae Min
    Cho, Sung-Yup
    Kim, Soyeon
    Ko, Donghyun
    Kim, Dong-Kyu
    Kim, Dong-Wan
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
    Duggirala, Krishna Babu
    Lee, Yujin
    Lee, Kwangho
    BIOMOLECULES & THERAPEUTICS, 2022, 30 (01) : 19 - 27
  • [5] H002: A wide spectrum, highly selective fourth-generation EGFR inhibitor overcoming resistance harboring C797S mutation in NSCLC
    Huang, Wei
    Zhu, Lin
    Yan, Xiaoe
    Huang, Xin
    Hao, Jia
    Li, Shan
    Li, Xiangyu
    Chen, Zhiming
    Jia, Yunchuan
    Li, Haibo
    Zhang, Jianming
    Deng, Xianming
    Yun, Caihong
    CANCER RESEARCH, 2022, 82 (12)
  • [6] Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs
    Zhao, Hong-Yi
    Xi, Xiao-Xiao
    Xin, Minhang
    Zhang, San-Qi
    BIOORGANIC CHEMISTRY, 2022, 128
  • [7] EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
    Wang, Shuhang
    Song, Yongping
    Liu, Delong
    CANCER LETTERS, 2017, 385 : 51 - 54
  • [8] The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation
    He, Jie
    Zhou, Zhihui
    Sun, Xin
    Yang, Zunhua
    Zheng, Pengwu
    Xu, Shan
    Zhu, Wufu
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 210
  • [9] Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future
    Zhang, Die
    Zhao, Jumei
    Yang, Yue
    Dai, Qiangfang
    Zhang, Ning
    Mi, Zhikuan
    Hu, Qianqian
    Liu, Xiaolong
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2025, 40 (01)
  • [10] Potent in vitro activity of Tarloxotinib for EGFR C797S and other mutations refractory to current EGFR tyrosine kinase inhibitors
    Suda, Kenichi
    Nishino, Masaya
    Koga, Takamasa
    Fujino, Toshio
    Kobayashi, Yoshihisa
    Mitsudomi, Tetsuya
    Vellanki, Avanish
    Tirunagaru, Vijaya G.
    CANCER RESEARCH, 2019, 79 (13)
12345